Oculis Holding AG (NASDAQ:OCS) Receives Average Recommendation of “Buy” from Brokerages

Oculis Holding AG (NASDAQ:OCS) has been given an average recommendation of “Buy” by the six research firms that are currently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have covered the stock in the last year is $30.17.

A number of equities research analysts have issued reports on OCS shares. Bank of America cut their price target on shares of Oculis from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, June 11th. Chardan Capital reissued a “buy” rating and issued a $30.00 price target on shares of Oculis in a report on Tuesday, June 11th. Robert W. Baird raised their price target on shares of Oculis from $35.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, June 11th. HC Wainwright raised their price target on shares of Oculis from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, June 11th. Finally, Wedbush reissued an “outperform” rating and issued a $29.00 price target on shares of Oculis in a report on Wednesday, March 6th.

Oculis Price Performance

OCS opened at $11.70 on Friday. The company has a 50 day moving average of $12.04 and a 200 day moving average of $11.83. The company has a market cap of $473.85 million, a PE ratio of -6.57 and a beta of 0.30. Oculis has a 12 month low of $9.05 and a 12 month high of $14.50. The company has a current ratio of 4.71, a quick ratio of 4.71 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last posted its earnings results on Wednesday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.03). Oculis had a negative return on equity of 52.72% and a negative net margin of 6,712.02%. The firm had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.28 million. On average, sell-side analysts expect that Oculis will post -1.9 EPS for the current year.

Institutional Investors Weigh In On Oculis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Searle & CO. purchased a new stake in Oculis during the 4th quarter worth approximately $112,000. Compagnie Lombard Odier SCmA grew its position in Oculis by 47.3% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after purchasing an additional 30,750 shares during the last quarter. Finally, abrdn plc purchased a new stake in Oculis during the 4th quarter worth approximately $15,980,000. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.